Drug intelligence / Profile preview

metronidazole + cefuroxime

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Intravenous
01

Overview

The combination of metronidazole and cefuroxime is a dual antibiotic therapy used to treat various bacterial infections. This combination leverages the complementary antimicrobial properties of both drugs to provide broad-spectrum coverage against both aerobic and anaerobic pathogens. ## Mechanism and Clinical Use Metronidazole is an antibiotic and antiprotozoal medication that is particularly effective against anaerobic bacteria and certain parasites. It works by entering bacterial cells and being reduced by bacterial enzymes to form reactive compounds that damage bacterial DNA, causing cell death. Cefuroxime is a second-generation cephalosporin antibiotic that works by binding to specific penicillin-binding proteins (PBPs) inside bacterial cell walls, inhibiting the final stage of bacterial cell wall synthesis. This leads to cell lysis mediated by bacterial autolytic enzymes. The combination is particularly useful for treating mixed infections where both aerobic and anaerobic bacteria may be present. Clinical studies have shown that cefuroxime plus metronidazole is an effective regimen for preventing postoperative infections, particularly in colorectal surgery. ## Clinical Applications This combination is commonly used for: - Abdominal (stomach area) infections - Colorectal surgery prophylaxis - Mixed aerobic and anaerobic infections - Intra-abdominal infections - Surgical prophylaxis, particularly for gastrointestinal procedures ## Administration and Dosing The combination is typically administered intravenously, with specific dosing regimens depending on the infection being treated. In clinical studies, regimens such as 1.5g cefuroxime plus 500mg metronidazole have been used as single doses for surgical prophylaxis. ## Safety Considerations While generally well-tolerated, this combination therapy has been associated with some adverse effects: - Transient factor V antibodies, which can result in prolonged PT and aPTT (blood clotting tests) - Potential for blood disorders, though these are rare - The usual side effects associated with each individual medication No direct drug interactions between cefuroxime and metronidazole have been documented, though this doesn't necessarily mean no interactions exist.

Other names
cefuroxime + metronidazolecefuroxime and metronidazole combination
02

Targets

PBP (Penicillin-binding protein family)Neuraminidase

Beyond the preview

Go deeper on metronidazole + cefuroxime.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on metronidazole + cefuroxime.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call